• 1
    American Cancer Society. Cancer statistics 2005: a presentation from the American Cancer Society. In: Cancer facts & figures 2005. American Cancer Society, 2005. Available at:
  • 2
    Canadian Cancer Society & National Cancer Institute of Canada. Canadian cancer statistics 2006. Toronto: 2006. Available at:
  • 3
    Du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:13209.
  • 4
    Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194200.
  • 5
    Biagi JJ, Eisenhauer EA. Systemic treatment policies in ovarian cancer: the next 10 years. Int J Gynecol Cancer 2003;13(Suppl. 2):23140.
  • 6
    Harries M, Gore M, Part I: chemotherapy for epithelial ovarian cancer—treatment at first diagnosis. Lancet Oncol 2002;3:52936.
  • 7
    Du Bois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16(Suppl. 8):viii712.
  • 8
    Schnik JC, Weller E, Harris LS et al. Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group phase II study (E2E93). Cancer J 2001;7:15564.
  • 9
    Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol 2006;17(Suppl. 5):v1817.
  • 10
    ICON. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:50515.
  • 11
    Bolis G, Scarfone G, Polverino G et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol 2004;22:68690.
  • 12
    McGuire WP, Hoskins W, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:16.
  • 13
    ICON. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 1998;352:15716.
  • 14
    Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699708.
  • 15
    Colombo N, Guthrie D, Chiari S et al. International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003;95:12532.
  • 16
    Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 2003;95:11325.
  • 17
    Trimbos JB, Parmar M, Vergote I et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:10512.
  • 18
    Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:3443.